ArticleInternational journal of women's health2025
Causal Analysis of Platelet Indices and Breast Cancer, Including Estrogen Receptor-Specific Subtypes: A Mendelian Randomization Study.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Significance of Pretreatment Mean Platelet Volume in Patients with Recurrent or De Novo Metastatic Breast Cancer: A Single-Center Retrospective Study.Breast cancer (Dove Medical Press) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Changes in platelet indices are associated with breast cancer. But the causal relationship between them remains unclear. Methods: Genetic variation data of platelet indices, including platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT), were collected as instrumental variables (IVs). We assessed their impact on the risk of overall breast cancer and its estrogen receptor (ER)+ and ER- subtypes through Mendelian randomization (MR) analysis, including IVs selection, multiple corrections, causality assessment, and sensitivity analysis. Additionally, the findings were validated using an independent dataset and extended the validation to East Asian populations. Results: Our results found that PCT was significantly associated with an increased risk of overall breast cancer (OR, 1.0693 [95% CI, 1.0281-1.1121]; P = 0.0008) and its ER+ subtype (OR, 1.0691 [95% CI, 1.0233-1.1169]; P = 0.0028), while they were suggestive evidence of a causal relationship after excluding the outliers determined by MR-PRESSO test. After removing the outliers, the suggestive evidence of a causal relationship between PLT and the increased risk of overall breast cancer (OR, 1.0351 [95% CI, 1.0003-1.0711]; P = 0.0483) disappeared, whereas MPV was suggestively associated with an increased risk of overall breast cancer (P = 0.0291). PDW was suggestively associated with a lower risk of overall breast cancer (OR, 0.9597 [95% CI, 0.9236-0.9971]; P = 0.035) and ER+ (OR, 0.9528 [95% CI, 0.9118-0.9957]; P = 0.0315), ER- (OR, 0.9199 [95% CI, 0.8644-0.979]; P = 0.0085) subtypes, whose outlier-corrected results were consistent with raw causal estimates. These findings were replicated in an independent dataset but did not generalize to the East Asian population. Conclusion: This study reveals suggestive evidence of a causal relationship between platelet indices, specifically PCT, MPV, and PDW, and the risk of breast cancer and its subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.